Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112340133 | 11234013 | 3 | F | 20150626 | 20160810 | 20150702 | 20160816 | EXP | BR-JNJFOC-20150621427 | JANSSEN | 48.13 | YR | A | F | Y | 79.00000 | KG | 20160816 | CN | BR | BR |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 112340133 | 11234013 | 1 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | Y | N | EJL85015A;ELL07013;EEL07011 +MORE | 0 | LYOPHILIZED POWDER | |||||||
| 112340133 | 11234013 | 2 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | Y | N | EJL85015A;ELL07013;EEL07011 +MORE | 0 | 385 | MG | LYOPHILIZED POWDER | |||||
| 112340133 | 11234013 | 3 | SS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | Y | N | EJL85015A;ELL07013;EEL07011 +MORE | 0 | 400 | MG | LYOPHILIZED POWDER | |||||
| 112340133 | 11234013 | 4 | PS | REMICADE | INFLIXIMAB | 1 | Intravenous (not otherwise specified) | Y | N | EJL85015A;ELL07013;EEL07011 +MORE | 103772 | 400 | MG | LYOPHILIZED POWDER | |||||
| 112340133 | 11234013 | 5 | C | LEVOTHYROXINE. | LEVOTHYROXINE | 1 | Unknown | 0 | 25 | MG | UNSPECIFIED | ||||||||
| 112340133 | 11234013 | 6 | C | DIAZEPAM. | DIAZEPAM | 1 | Unknown | 0 | 5 | MG | UNSPECIFIED | ||||||||
| 112340133 | 11234013 | 7 | C | OMEPRAZOLE. | OMEPRAZOLE | 1 | Unknown | 0 | 20 | MG | UNSPECIFIED | ||||||||
| 112340133 | 11234013 | 8 | C | ENALAMED | 2 | 0 | |||||||||||||
| 112340133 | 11234013 | 9 | C | HYDROCHLOROTHIAZIDE. | HYDROCHLOROTHIAZIDE | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 112340133 | 11234013 | 1 | Psoriasis |
| 112340133 | 11234013 | 2 | Psoriasis |
| 112340133 | 11234013 | 3 | Psoriasis |
| 112340133 | 11234013 | 4 | Psoriasis |
| 112340133 | 11234013 | 6 | Depression |
| 112340133 | 11234013 | 7 | Gastrointestinal disorder therapy |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 112340133 | 11234013 | LT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 112340133 | 11234013 | Dyspnoea | |
| 112340133 | 11234013 | Flushing | |
| 112340133 | 11234013 | Infusion related reaction | |
| 112340133 | 11234013 | Malaise |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 112340133 | 11234013 | 1 | 20151216 | 0 | ||
| 112340133 | 11234013 | 4 | 20150626 | 0 | ||
| 112340133 | 11234013 | 5 | 2010 | 0 | ||
| 112340133 | 11234013 | 6 | 2015 | 0 | ||
| 112340133 | 11234013 | 7 | 2010 | 0 |